RU2014126244A - Лекарственные средства, содержащие аминокислотные последовательности инсулина - Google Patents
Лекарственные средства, содержащие аминокислотные последовательности инсулина Download PDFInfo
- Publication number
- RU2014126244A RU2014126244A RU2014126244A RU2014126244A RU2014126244A RU 2014126244 A RU2014126244 A RU 2014126244A RU 2014126244 A RU2014126244 A RU 2014126244A RU 2014126244 A RU2014126244 A RU 2014126244A RU 2014126244 A RU2014126244 A RU 2014126244A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- amino acid
- composition according
- acid sequence
- chain
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract 14
- 102000004877 Insulin Human genes 0.000 title claims abstract 8
- 108090001061 Insulin Proteins 0.000 title claims abstract 8
- 229940125396 insulin Drugs 0.000 title claims abstract 7
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 47
- 239000012730 sustained-release form Substances 0.000 claims abstract 11
- 238000013268 sustained release Methods 0.000 claims abstract 10
- 239000007924 injection Substances 0.000 claims abstract 5
- 238000002347 injection Methods 0.000 claims abstract 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 4
- 230000002641 glycemic effect Effects 0.000 claims abstract 3
- 230000007774 longterm Effects 0.000 claims abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract 3
- 238000010521 absorption reaction Methods 0.000 claims abstract 2
- 238000012217 deletion Methods 0.000 claims abstract 2
- 230000037430 deletion Effects 0.000 claims abstract 2
- 238000003780 insertion Methods 0.000 claims abstract 2
- 230000037431 insertion Effects 0.000 claims abstract 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 238000006467 substitution reaction Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 8
- 235000018102 proteins Nutrition 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 229920001222 biopolymer Polymers 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000002354 daily effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 235000004554 glutamine Nutrition 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 9
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563985P | 2011-11-28 | 2011-11-28 | |
| US61/563,985 | 2011-11-28 | ||
| PCT/US2012/066795 WO2013082116A1 (en) | 2011-11-28 | 2012-11-28 | Therapeutic agents comprising insulin amino acid sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014126244A true RU2014126244A (ru) | 2016-01-27 |
Family
ID=48536000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014126244A RU2014126244A (ru) | 2011-11-28 | 2012-11-28 | Лекарственные средства, содержащие аминокислотные последовательности инсулина |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20130150291A1 (enExample) |
| EP (1) | EP2785367A4 (enExample) |
| JP (1) | JP2014534265A (enExample) |
| KR (1) | KR20140103985A (enExample) |
| CN (1) | CN104080473A (enExample) |
| AU (1) | AU2012346058A1 (enExample) |
| BR (1) | BR112014012789A2 (enExample) |
| CA (1) | CA2856967A1 (enExample) |
| HK (1) | HK1202067A1 (enExample) |
| IL (1) | IL232781A0 (enExample) |
| MX (1) | MX2014006391A (enExample) |
| RU (1) | RU2014126244A (enExample) |
| SG (1) | SG11201402661TA (enExample) |
| WO (1) | WO2013082116A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| CN105727261A (zh) | 2008-06-27 | 2016-07-06 | 杜克大学 | 包含弹性蛋白样肽的治疗剂 |
| ES2669190T3 (es) | 2011-06-06 | 2018-05-24 | Phasebio Pharmaceuticals, Inc. | Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión |
| US20150290328A1 (en) | 2012-11-20 | 2015-10-15 | Phasebio Pharmaceuticals, Inc. | Formulations of active agents for sustained release |
| EP2945643A4 (en) * | 2013-01-15 | 2017-04-26 | Phasebio Pharmaceuticals, Inc. | Therapeutic agents, compositions, and methods for glycemic control |
| EP3139949B1 (en) | 2014-05-08 | 2020-07-29 | Phasebio Pharmaceuticals, Inc. | Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis |
| JPWO2015178466A1 (ja) * | 2014-05-21 | 2017-04-20 | 味の素株式会社 | フィブロイン様タンパク質の製造法 |
| EP3220936A4 (en) * | 2014-11-21 | 2018-08-22 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
| ES2822598T3 (es) | 2015-02-09 | 2021-05-04 | Phasebio Pharmaceuticals Inc | Métodos y composiciones para tratar enfermedades y trastornos musculares |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| EP3124495A1 (en) * | 2015-07-31 | 2017-02-01 | Centre National de la Recherche Scientifique (C.N.R.S.) | Derivatives of elastin-like polypeptides and uses thereof |
| US11458205B2 (en) | 2015-08-04 | 2022-10-04 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
| CN105061566A (zh) * | 2015-09-05 | 2015-11-18 | 苏州普罗达生物科技有限公司 | 拟胰岛素多肽及其应用 |
| JP2018531007A (ja) * | 2015-09-24 | 2018-10-25 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリンの製造方法 |
| KR101815080B1 (ko) | 2015-11-03 | 2018-01-04 | 재단법인대구경북과학기술원 | 췌장소도세포 및 엘라스틴 유사 인공 세포외 기질을 포함하는 당뇨병 치료용 약학적 조성물 |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| MX395130B (es) | 2016-03-02 | 2025-03-24 | Merz Pharma Gmbh & Co Kgaa | Composicion que comprende toxina botulinica |
| WO2017189860A1 (en) | 2016-04-27 | 2017-11-02 | The Regents Of The University Of California | Preparation of functional homocysteine residues in polypeptides and peptides |
| KR102646323B1 (ko) | 2016-05-06 | 2024-03-13 | 이뮤노포지 주식회사 | 제어된 지속 방출을 위한 elp 융합 단백질 |
| WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
| KR20190064600A (ko) | 2016-09-23 | 2019-06-10 | 듀크 유니버시티 | Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드 |
| US11220467B2 (en) | 2017-01-11 | 2022-01-11 | Recycle Track Systems, Inc. | Indoor food waste fermentation and recycling process |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| EP3642222A1 (en) | 2017-06-20 | 2020-04-29 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with increased duration of effect |
| EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS |
| US11155802B2 (en) | 2017-07-06 | 2021-10-26 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum neurotoxins with increased duration of effect |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| WO2019213150A1 (en) | 2018-04-30 | 2019-11-07 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| EP3829622A4 (en) | 2018-08-02 | 2022-05-11 | Duke University | DOUBLE AGONIST FUSION PROTEINS |
| WO2020051541A1 (en) | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| KR102456958B1 (ko) * | 2019-05-14 | 2022-10-21 | 강원대학교 산학협력단 | 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물 |
| CN111939244B (zh) * | 2019-05-14 | 2024-08-06 | 阿莫生命科学有限公司 | 用于预防或治疗糖尿病并发症的药物组合物 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| US12435116B2 (en) | 2019-10-16 | 2025-10-07 | Clarence Hurt | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome |
| JPWO2021112249A1 (enExample) * | 2019-12-06 | 2021-06-10 | ||
| WO2026015937A1 (en) * | 2024-07-15 | 2026-01-22 | The University Of Melbourne | Novel treatment for diabetes and obesity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309955A1 (en) * | 1997-11-12 | 1999-05-20 | Alza Corporation | Method for decreasing self-association of polypeptides |
| US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| EP1971355B1 (en) * | 2005-12-20 | 2020-03-11 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| WO2007095337A2 (en) * | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Antibody formulation |
| CN101438158A (zh) * | 2006-03-06 | 2009-05-20 | 阿穆尼克斯股份有限公司 | 遗传包和其应用 |
| CN105727261A (zh) * | 2008-06-27 | 2016-07-06 | 杜克大学 | 包含弹性蛋白样肽的治疗剂 |
| WO2010014689A1 (en) * | 2008-07-29 | 2010-02-04 | Phasebio Pharmaceuticals, Inc. | Pharmaceutical formulations comprising elastin-like proteins |
| DK2459171T3 (en) * | 2009-07-31 | 2017-09-25 | Sanofi Aventis Deutschland | Long-acting insulin composition |
| IN2012DN02120A (enExample) * | 2009-08-14 | 2015-08-21 | Phasebio Pharmaceuticals Inc |
-
2012
- 2012-11-28 MX MX2014006391A patent/MX2014006391A/es unknown
- 2012-11-28 SG SG11201402661TA patent/SG11201402661TA/en unknown
- 2012-11-28 BR BR112014012789A patent/BR112014012789A2/pt not_active IP Right Cessation
- 2012-11-28 US US13/687,776 patent/US20130150291A1/en not_active Abandoned
- 2012-11-28 JP JP2014543618A patent/JP2014534265A/ja active Pending
- 2012-11-28 CA CA2856967A patent/CA2856967A1/en not_active Abandoned
- 2012-11-28 RU RU2014126244A patent/RU2014126244A/ru not_active Application Discontinuation
- 2012-11-28 CN CN201280068260.1A patent/CN104080473A/zh active Pending
- 2012-11-28 WO PCT/US2012/066795 patent/WO2013082116A1/en not_active Ceased
- 2012-11-28 HK HK15102642.1A patent/HK1202067A1/xx unknown
- 2012-11-28 KR KR1020147017232A patent/KR20140103985A/ko not_active Withdrawn
- 2012-11-28 EP EP12852785.0A patent/EP2785367A4/en not_active Withdrawn
- 2012-11-28 AU AU2012346058A patent/AU2012346058A1/en not_active Abandoned
-
2014
- 2014-05-25 IL IL232781A patent/IL232781A0/en unknown
- 2014-06-13 US US14/304,617 patent/US20140364362A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2856967A1 (en) | 2013-06-06 |
| AU2012346058A1 (en) | 2014-06-12 |
| WO2013082116A1 (en) | 2013-06-06 |
| BR112014012789A2 (pt) | 2019-09-24 |
| HK1202067A1 (en) | 2015-09-18 |
| US20130150291A1 (en) | 2013-06-13 |
| JP2014534265A (ja) | 2014-12-18 |
| IL232781A0 (en) | 2014-07-31 |
| KR20140103985A (ko) | 2014-08-27 |
| CN104080473A (zh) | 2014-10-01 |
| EP2785367A4 (en) | 2015-06-17 |
| SG11201402661TA (en) | 2014-08-28 |
| MX2014006391A (es) | 2014-09-22 |
| EP2785367A1 (en) | 2014-10-08 |
| US20140364362A1 (en) | 2014-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534265A5 (enExample) | ||
| CN102026666B (zh) | 促胰岛素肽缀合物制剂 | |
| US11174303B2 (en) | Single-chain insulin analogues stabilized by a fourth disulfide bridge | |
| JP6829928B2 (ja) | 二相性単鎖インスリン類似体 | |
| CN105008395B (zh) | 长效单链胰岛素类似物 | |
| CA2729938A1 (en) | New insulin analogues of prolonged activity | |
| JP2010502734A5 (enExample) | ||
| CN102718858A (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| CA2873553C (en) | Use of modified vasoactive intestinal peptides in the treatment of hypertension | |
| CN104010652A (zh) | 超浓缩的速效胰岛素类似物制剂 | |
| CA3134538A1 (en) | Formulations of protein molecules comprising iduronate 2-sulfatase | |
| JP2022507627A (ja) | ポリ－アラニンｃ－ドメインのサブセグメントを有する単鎖インスリンアナログ | |
| JP2013513391A (ja) | 塩素化アミノ酸を有するインスリン類似体 | |
| WO2013110069A1 (en) | Glutamic acid-stabilized insulin analogues | |
| CA2856967A1 (en) | Therapeutic agents comprising insulin amino acid sequences | |
| CA3139946A1 (en) | Variant single-chain insulin analogues | |
| JP2013516464A5 (enExample) | ||
| TW200520770A (en) | Glp-1 pharmaceutical compositions | |
| KR102568272B1 (ko) | Ｇｌｐ-1ｒ 항체 융합 단백질의 안정한 약제학적 용액 제형 | |
| EP3541397A1 (en) | Rapid-acting insulin analogues of enhanced stability | |
| JP2017537065A (ja) | 生物学的作用強度の高いハロゲン化インスリン類似体 | |
| WO2015180634A1 (zh) | 用于治疗2型糖尿病的长效肠激素多肽类似物及应用 | |
| JP2019522046A5 (enExample) | ||
| RU2018145945A (ru) | Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170515 |